vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»vsp-1313Research ArticleОБЗОРЫ ЛИТЕРАТУРЫLITERATURE REVIEWАТОПИЧЕСКИЙ ДЕРМАТИТ У ДЕТЕЙ: ЗОНА КЛИНИЧЕСКОГО КОНТРОЛЯATOPIC DERMATITIS AMONG CHILDREN: ZONE OF CLINICAL SUPERVISIONОгородоваЛ.М.OgorodovaL.M.ДееваЕ.В.DeevaE.V.ДеевИ.А.DeevI.A.Сибирский государственный медицинский университет, ТомскРоссияSiberian State Medical University, TomskRussian Federation20072110201566Вопросы современной педиатрии6469Copyright © Огородова Л., Деева Е., Деев И., 20072007Огородова Л., Деева Е., Деев И.Ogorodova L., Deeva E., Deev I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/1313ReferencesАтопический дерматит и инфекции кожи у детей: диагностика, лечение, профилактика. Научно-практическая программа Союза педиатров России. М. 2004. 52 с.Атопический дерматит и инфекции кожи у детей: диагностика, лечение, профилактика. Научно-практическая программа Союза педиатров России. М. 2004. 52 с.Williams H.C. Diagnostic criteria for atopic dermatitis: where do we go from here? Arch. Dermatol. 1999; 135 (5): 583–586.Williams H.C. Diagnostic criteria for atopic dermatitis: where do we go from here? Arch. Dermatol. 1999; 135 (5): 583–586.Rudikoff D., Lebwohl M. Atopic dermatitis. Lancet. 1998; 6 (351): 1715–1721.Rudikoff D., Lebwohl M. Atopic dermatitis. Lancet. 1998; 6 (351): 1715–1721.Boguniewicz M., Fiedler V.C., Raimer S. et al. Randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J. Allergy Clin. Immunol. 1998; 102: 637–644.Boguniewicz M., Fiedler V.C., Raimer S. et al. Randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J. Allergy Clin. Immunol. 1998; 102: 637–644.Sugiura H., Umemoto N., Deguchi H. et al. Prevalence of childhood and adolescent atopic dermatitis in a Japanese population: comparison with the disease frequency examined 20 years ago. Acta Derm. Venereol. 1998; 78 (4): 293–254.Sugiura H., Umemoto N., Deguchi H. et al. Prevalence of childhood and adolescent atopic dermatitis in a Japanese population: comparison with the disease frequency examined 20 years ago. Acta Derm. Venereol. 1998; 78 (4): 293–254.Современная стратегия терапии атопического дерматита: программа действий педиатра Согласительный документ ассоциации детских аллергологов-иммунологов России. М. 2004. 96 с.Современная стратегия терапии атопического дерматита: программа действий педиатра Согласительный документ ассоциации детских аллергологов-иммунологов России. М. 2004. 96 с.Kay J., Gawkrodger D.J., Mortimer M.J., et al. The prevalence of childhood atopic eczema in a general population. J. Am. Acad. Dermatol. 1994; 30 (1): 35–39.Kay J., Gawkrodger D.J., Mortimer M.J., et al. The prevalence of childhood atopic eczema in a general population. J. Am. Acad. Dermatol. 1994; 30 (1): 35–39.Reid P., Lewis-Jones M.S. Sleep difficulties and their management in preschoolers with atopic eczema. Clin. Exp. Dermatol. 1995; 20 (1): 38–41.Reid P., Lewis-Jones M.S. Sleep difficulties and their management in preschoolers with atopic eczema. Clin. Exp. Dermatol. 1995; 20 (1): 38–41.Lawson V., Lewis-Jones M.S., Finlay A.Y. The family impact of childhood atopic dermatitis: the Dermatitis Family Impact Questionnaire. Br. J. Dermatol. 1998; 138 (1): 107–113.Lawson V., Lewis-Jones M.S., Finlay A.Y. The family impact of childhood atopic dermatitis: the Dermatitis Family Impact Questionnaire. Br. J. Dermatol. 1998; 138 (1): 107–113.Elliott B.E., Luker K. The experiences of mothers caring for a child with severe atopic eczema. J. Clin. Nurs. 1997; 6 (3): 241–247.Elliott B.E., Luker K. The experiences of mothers caring for a child with severe atopic eczema. J. Clin. Nurs. 1997; 6 (3): 241–247.Ревякина В.А., Огородова Л.М., Деев И.А. и др. Результаты Национального многоцентрового клинико-эпидемиологического исследования атопического дерматита у детей. Аллергология. 2006; 1: 3–10.Ревякина В.А., Огородова Л.М., Деев И.А. и др. Результаты Национального многоцентрового клинико-эпидемиологического исследования атопического дерматита у детей. Аллергология. 2006; 1: 3–10.Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology American Academy of Allergy, Asthma and Immunology. PRACTALL Consensus Report. J. Allergy. 2006; 61: 969–987.Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology American Academy of Allergy, Asthma and Immunology. PRACTALL Consensus Report. J. Allergy. 2006; 61: 969–987.Giusti F., Matrella A., Bertony L. Skin barrier, hydration, and pH of the skin of infants under 2 years of age. Ped. Derm. 2001; 18: 93–96.Giusti F., Matrella A., Bertony L. Skin barrier, hydration, and pH of the skin of infants under 2 years of age. Ped. Derm. 2001; 18: 93–96.Walsh P., Aeling J.L., Huff L. Hypothalamus-pituitary-adrenal axis suppression by superpotent steroids. J. Am. Acad. Dermatol. 1993; 29: 501–503.Walsh P., Aeling J.L., Huff L. Hypothalamus-pituitary-adrenal axis suppression by superpotent steroids. J. Am. Acad. Dermatol. 1993; 29: 501–503.Zachariae H. Renal toxicity of long-term cyclosporine. Scand. J. Reumatol. 1999; 28: 65-68.Zachariae H. Renal toxicity of long-term cyclosporine. Scand. J. Reumatol. 1999; 28: 65-68.Wahn U., Bos J.D., Goodfield M. et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics. 2002; 110: 2.Wahn U., Bos J.D., Goodfield M. et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics. 2002; 110: 2.Harper J., Green A., Scott G. et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br. J. Dermatol. 2001; 144 (4): 781–787.Harper J., Green A., Scott G. et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br. J. Dermatol. 2001; 144 (4): 781–787.Breuer K., Werfel T., Kapp A. Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis. Am. J. Clin. Dermatol. 2005; 6 (2): 65–77.Breuer K., Werfel T., Kapp A. Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis. Am. J. Clin. Dermatol. 2005; 6 (2): 65–77.Simon D., Lubbe J., Wuthrich B. et al. Benefits from the use of a pimecrolimus based treatment in the management of atopic dermatitis in clinical practice. Analysis of a Swiss cohort. Dermatology. 2006; 213 (4): 313–318.Simon D., Lubbe J., Wuthrich B. et al. Benefits from the use of a pimecrolimus based treatment in the management of atopic dermatitis in clinical practice. Analysis of a Swiss cohort. Dermatology. 2006; 213 (4): 313–318.Papp K.A., Breuer K., Meurer M. et al. Long term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. J. Am. Acad. Dermatol. 2005; 52 (2): 247–253.Papp K.A., Breuer K., Meurer M. et al. Long term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. J. Am. Acad. Dermatol. 2005; 52 (2): 247–253.Papp K.A., Werfel T., Folster-Holst R. et al. Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two year study. J. Am. Acad. Dermatol. 2005; 52 (2): 240–246.Papp K.A., Werfel T., Folster-Holst R. et al. Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two year study. J. Am. Acad. Dermatol. 2005; 52 (2): 240–246.Hultsch T., Kapp A., Spergel J. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology. 2005; 211 (2): 174–187.Hultsch T., Kapp A., Spergel J. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology. 2005; 211 (2): 174–187.Meurer M., Fartasch M., Albrecht G. et al. Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology. 2004; 208 (4): 365–372.Meurer M., Fartasch M., Albrecht G. et al. Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology. 2004; 208 (4): 365–372.Gupta A.K., Chow M. Pimecrolimus: a review. J. Eur. Acad. Dermatol. Venereol. 2003; 17 (5): 493–503.Gupta A.K., Chow M. Pimecrolimus: a review. J. Eur. Acad. Dermatol. Venereol. 2003; 17 (5): 493–503.Eichenfield L.F., Lucky A.W., Langley R.G. et al. Use of pimecrolimus cream 1% (Elidel) in the treatment of atopic dermatitis in infants and children: the effects of ethnic origin and baseline disease severity on treatment outcome. Int. J. Dermatol. 2005; 44 (1): 70–75.Eichenfield L.F., Lucky A.W., Langley R.G. et al. Use of pimecrolimus cream 1% (Elidel) in the treatment of atopic dermatitis in infants and children: the effects of ethnic origin and baseline disease severity on treatment outcome. Int. J. Dermatol. 2005; 44 (1): 70–75.Lubbe J., Friedlander S.F., Cribier B. et al. Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice. Am. J. Clin. Dermatol. 2006; 7 (2): 121–131.Lubbe J., Friedlander S.F., Cribier B. et al. Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice. Am. J. Clin. Dermatol. 2006; 7 (2): 121–131.Kapp A., Papp K., Bingham A. et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti–inflammatory drug. J. Allergy Clin. Immunol. 2002; 110 (2): 277–284.Kapp A., Papp K., Bingham A. et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti–inflammatory drug. J. Allergy Clin. Immunol. 2002; 110 (2): 277–284.McKenna S.P., Whalley D., de Prost Y. et al. Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel, SDZ ASM 981): impact on quality of life and health-related quality of life. J. Eur. Acad. Dermatol. Venereol. 2006; 20 (3): 248–254.McKenna S.P., Whalley D., de Prost Y. et al. Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel, SDZ ASM 981): impact on quality of life and health-related quality of life. J. Eur. Acad. Dermatol. Venereol. 2006; 20 (3): 248–254.Staab D., Kaufmann R., Brautigam M., Wahn U. Treatment of infants with atopic eczema with pimecrolimus cream 1% improves parents' quality of life: a multicenter, randomized trial. Pediatr. Allerg Immunol. 2005; 16 (6): 527–533.Staab D., Kaufmann R., Brautigam M., Wahn U. Treatment of infants with atopic eczema with pimecrolimus cream 1% improves parents' quality of life: a multicenter, randomized trial. Pediatr. Allerg Immunol. 2005; 16 (6): 527–533.Staab D., Pariser D., Gottlieb A.B. et al. Low systemic absorption and good tolerability of pimecrolimus, administered as 1% cream (Elidel) in infants with atopic dermatitis a multicenter, 3-week, open-label study. Pediatr. Dermatol. 2005; 22 (5): 465–471.Staab D., Pariser D., Gottlieb A.B. et al. Low systemic absorption and good tolerability of pimecrolimus, administered as 1% cream (Elidel) in infants with atopic dermatitis a multicenter, 3-week, open-label study. Pediatr. Dermatol. 2005; 22 (5): 465–471.Whalley D., Huels J., McKenna S.P., Van Assche D. The benefit of pimecrolimus (Elidel, SDZ ASM 981) on parents' quality of life in the treatment of pediatric atopic dermatitis. Pediatrics. 2002; 110 (6): 1133–1136.Whalley D., Huels J., McKenna S.P., Van Assche D. The benefit of pimecrolimus (Elidel, SDZ ASM 981) on parents' quality of life in the treatment of pediatric atopic dermatitis. Pediatrics. 2002; 110 (6): 1133–1136.Fowler J., Johnson A., Chen M., Abrams K. Improvement in pruritus in children with atopic dermatitis using pimecrolimus cream 1%. Cutis. 2007; 79 (1): 65–72.Fowler J., Johnson A., Chen M., Abrams K. Improvement in pruritus in children with atopic dermatitis using pimecrolimus cream 1%. Cutis. 2007; 79 (1): 65–72.Смирнова Г.И. Современная концепция лечения атопического дерматита у детей. М. 2006. 132 с.Смирнова Г.И. Современная концепция лечения атопического дерматита у детей. М. 2006. 132 с.
The authors declare that there are no conflicts of interest present.